Labcorp director Richelle Parham sells $389,395 in shares

Labcorp director Richelle Parham divested 1,078 shares of common stock on October 30, 2026, generating $389,395 from the sale. The shares were exchanged at $361.22 per unit, reflecting the stock's proximity to its 52-week peak of $373.34. Year-to-date, the stock has surged 47%. Market analysis suggests Labcorp shares are currently overpriced compared to their intrinsic value.

Parham retains a stake of 2,288 Labcorp shares after the transaction. Meanwhile, Laboratory Corporation of America Holdings released robust third-quarter 2026 figures, beating analyst estimates with adjusted earnings of $4.78 per share and revenue of $3.81 billion. This outperformance is attributed to robust organic growth and margin expansion, marking the sixth consecutive quarter of enhanced enterprise margins.

Free cash flow also increased by 46.6% to $412 million, bolstering capital returns and acquisition potential. Management has raised its 2026 outlook, citing sustained strength in diagnostics and biopharma services. Following the financial results, Truist Securities upgraded its price target for Labcorp shares to $395 from $365, maintaining a Buy rating.

The firm attributed the positive outlook to Labcorp's strong quarterly performance, particularly improvements in margins across various business segments. These developments underline the company's overall operational health, with enterprise revenue growing 6.9% year-over-year.